Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Summary
AMLX Earnings Beat Rate & Surprise History
Amylyx Pharmaceuticals, Inc. (AMLX) has beaten EPS estimates in 2 of its last 9 reported quarters (+22%), and beaten revenue estimates in 1 of 4 (+25%).
On balance, analysts have tended to overestimate AMLX's earnings. It is currently on a 3-quarter EPS miss streak. The stock has averaged -5.9% the trading day after an EPS beat (positive 0% of the time) and -1.1% after a miss. The average EPS surprise runs -48.8%, with the biggest beat at +18.8% and the biggest miss at -360.8%.
How often AMLX has cleared Wall Street's bar, for EPS and revenue separately, companies can beat one and miss the other. See how analysts are rating it now →
Based on 10 quarters where a report date lines up with price history on record. Reaction day is determined from report timing, for after-market-close (AMC) reports, the reaction shows up the next trading day; for before-market-open (BMO) reports, it's the report day itself.
| Result | Next day | 5 trading days | 20 trading days |
|---|---|---|---|
| EPS beat | -5.9% (0% pos, n=2) | -6.7% (0% pos, n=2) | +8.3% (100% pos, n=2) |
| EPS miss | -1.1% (29% pos, n=7) | -2.8% (43% pos, n=7) | -0.2% (33% pos, n=6) |
Average earnings-day move (either direction): +5.2%. Largest on record: +10.7%.
Every quarter with reaction data, side by side. Rows where the surprise direction and the stock's move disagree are highlighted.
| Quarter | Report Date | EPS Surprise | Rev Surprise | Next-Day Move |
|---|---|---|---|---|
| Q2 '26 | Aug 6, 2026 | -11.4% | — | +10.7% |
| Q1 '26 | May 7, 2026 | -7.4% | — | -5.4% |
| Q4 '25 | Mar 3, 2026 | -1.8% | +100.0% | -7.8% |
| Q3 '25 | Nov 6, 2025 | +18.8% | -100.0% | -5.9% |
| Q2 '25 | Aug 7, 2025 | -4.1% | — | -4.3% |
| Q1 '25 | May 8, 2025 | +6.9% | — | -6.0% |
| Q4 '24 | Mar 4, 2025 | — | — | +0.3% |
| Q3 '24 | Nov 7, 2024 | -66.9% | — | +5.1% |
| Q2 '24 | Aug 8, 2024 | -12.5% | -109.6% | -4.3% |
| Q1 '24 | May 9, 2024 | -360.8% | -9.9% | -2.1% |
Beat/miss alone doesn't say how big, a company that beats by 0.1% every quarter behaves very differently from one that swings ±20%.
| Avg Surprise | Median | Largest Beat | Largest Miss | |
|---|---|---|---|---|
| EPS | -48.8% | -7.4% | +18.8% | -360.8% |
| Revenue | -29.9% | -55.0% | +100.0% | -109.6% |
More analysts covering a stock generally means more scrutiny and (often) tighter estimates.
Average surprise size by fiscal quarter, some businesses are just more predictable in certain quarters than others.
| Fiscal Quarter | Avg EPS Surprise | Avg Revenue Surprise | Years on Record |
|---|---|---|---|
| Q1 | -120.4% | -9.9% | 3 |
| Q2 | -9.4% | -109.6% | 3 |
| Q3 | -24.0% | -100.0% | 2 |
| Q4 | -1.8% | +100.0% | 2 |
Each quarter compared to the same fiscal quarter one year earlier, the standard way to strip out seasonality.
| Quarter | Report Date | EPS Growth | Revenue Growth |
|---|---|---|---|
| Q2 '26 | Aug 6, 2026 | +17.0% | — |
| Q1 '26 | May 7, 2026 | +11.9% | — |
| Q4 '25 | Mar 3, 2026 | +45.5% | +100.0% |
| Q3 '25 | Nov 6, 2025 | +65.4% | -100.0% |
| Q2 '25 | Aug 7, 2025 | +56.1% | +100.0% |
| Q1 '25 | May 8, 2025 | +76.0% | -100.0% |
Objective, rule-based checks, not a subjective rating.
How often does AMLX beat EPS estimates?
Amylyx Pharmaceuticals, Inc. has beaten EPS estimates in 2 of its last 9 reported quarters, a +22% beat rate. The average surprise is -48.8%.
How often does AMLX beat revenue estimates?
AMLX has beaten revenue estimates in 1 of its last 4 reported quarters, a +25% beat rate.
How does AMLX's stock react to earnings?
Over 10 quarters with price data on record, AMLX has averaged -5.9% the trading day after an EPS beat (positive 0% of the time) and -1.1% after a miss (positive 29% of the time).
What is AMLX's biggest earnings surprise?
AMLX's largest EPS beat on record is +18.8%, and its largest EPS miss is -360.8%.
Is AMLX currently on an earnings beat or miss streak?
AMLX is on a 3-quarter EPS miss streak. Its longest beat streak on record is 1 quarters; its longest miss streak is 3 quarters.
Do analysts usually underestimate or overestimate AMLX?
Analysts have tended to overestimate AMLX's results, based on a +22% EPS beat rate over the last 9 reported quarters.
Every reported quarter on record, estimate vs. actual.
| Quarter | Report Date | EPS Est | EPS Actual | EPS Surprise | Revenue Est | Revenue Actual | Revenue Surprise | Analysts |
|---|---|---|---|---|---|---|---|---|
| Q2 '26 | Aug 6, 2026 | -$0.35 | -$0.39 | -11.4% | $0.00 | $0.00 | — | 3 |
| Q1 '26 | May 7, 2026 | -$0.35 | -$0.37 | -7.4% | $0.00 | $0.00 | — | 3 |
| Q4 '25 | Mar 3, 2026 | -$0.29 | -$0.30 | -1.8% | -$52.0K | $0.00 | +100.0% | 3 |
| Q3 '25 | Nov 6, 2025 | -$0.45 | -$0.37 | +18.8% | $52.0K | $0.00 | -100.0% | 3 |
| Q2 '25 | Aug 7, 2025 | -$0.45 | -$0.47 | -4.1% | $0.00 | $0.00 | — | 3 |
| Q1 '25 | May 8, 2025 | -$0.45 | -$0.42 | +6.9% | $0.00 | $0.00 | — | 1 |
| Q4 '24 | Mar 4, 2025 | — | -$0.55 | — | $0.00 | -$665.0K | — | — |
| Q3 '24 | Nov 7, 2024 | -$0.64 | -$1.07 | -66.9% | $0.00 | $416.0K | — | 1 |
| Q2 '24 | Aug 8, 2024 | -$0.95 | -$1.07 | -12.5% | $10.66M | -$1.02M | -109.6% | 1 |
| Q1 '24 | May 9, 2024 | -$0.38 | -$1.75 | -360.8% | $98.35M | $88.60M | -9.9% | 1 |